There are isolated reports of the potential efficacy of peripheral CB1 antagonists in people suffering from Prader-Willi syndrome (with advanced obesity and hyperphagia) [177]. This evidence concerns the gene CNR1 and obesity due to melanocortin 4 receptor deficiency.